依普利酮在国内的价格是多少？

What is the price in China? There is no relevant introduction to the domestic launch of eplerenone, so eplerenone has no domestic price, and we do not know the domestic price of eplerenone.

Eplerenone is a new generation of selective aldosterone antagonist, developed and produced by Pfizer/Pharmacia, with the trade name Inspra. In 2002, eplerenone was approved in the United States and was launched to treat hypertension and heart failure. and patients with myocardial infarction. Eplerenone has a stronger antagonizing effect on aldosterone than spironolactone, and has extremely low affinity for androgen and progesterone receptors. It has few adverse reactions. It has definite efficacy in the treatment of hypertension, heart failure and myocardial infarction, has fewer adverse reactions and is well tolerated. It is a good alternative drug to spironolactone.

Pharmacological effects of eplerenone: Eplerenone is a selective aldosterone receptor antagonist that only acts on mineralocorticoid receptors and does not act on androgen and progesterone receptors. Eplerenone treats patients with stage 1 and 2 hypertension with similar effectiveness and magnitude in reducing systolic and diastolic blood pressure as enalapril.

Eplerenone also has a good antihypertensive effect in patients with essential hypertension with low renin levels for whom angiotensin-converting enzyme inhibitors and angiotensin II receptor inhibitors are ineffective. It also has a good antihypertensive effect on simple systolic hypertension, and has a good antihypertensive effect on diet-induced obesity-related hypertension.

In addition, (eplerenone) can significantly reduce the ultrafiltration effect of glomeruli and reduce albuminuria in patients with hypertension. This renal protective effect is more obvious for hypertensive patients with diabetes.